Skip to content
Biodatica
Start free

Bristol-Myers Squibb

Chandler, Arizona

OncologyantibodyPhase IIIListed · BMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

3d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Sep 15, 2026

    Arthritis, Rheumatoid · NOT_YET_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

    ClinicalTrials.gov · NCT07412704 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jun 30, 2026

    Healthy Volunteers · NOT_YET_RECRUITING · sponsor: Bristol-Myers Squibb · Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

    ClinicalTrials.gov · NCT07629999 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Feb 19, 2026

    Healthy Volunteers · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

    ClinicalTrials.gov · NCT07422298 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Dec 15, 2025

    Healthy Volunteers, Hepatic Impairment · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

    ClinicalTrials.gov · NCT07248839 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Dec 2, 2025

    Alzheimer Disease, Agitation · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    ClinicalTrials.gov · NCT06937229 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Nov 12, 2025

    Healthy Volunteers · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

    ClinicalTrials.gov · NCT07226817 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Oct 15, 2025

    Advanced Solid Tumors · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT07077434 (opens the source filing in a new tab)

  8. Trial

    PHASE1/PHASE2 registered

    Oct 15, 2025

    Solid Tumours · RECRUITING · sponsor: Bristol-Myers Squibb · A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT07160725 (opens the source filing in a new tab)

  9. Trial

    PHASE3 registered

    Jul 16, 2025

    Alzheimer Disease · RECRUITING · sponsor: Bristol-Myers Squibb · A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

    ClinicalTrials.gov · NCT07011745 (opens the source filing in a new tab)

  10. Trial

    PHASE1 registered

    May 7, 2025

    Small Cell Lung Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

    ClinicalTrials.gov · NCT06799286 (opens the source filing in a new tab)

  11. Trial

    PHASE1 registered

    May 5, 2025

    Healthy Volunteer · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

    ClinicalTrials.gov · NCT06955741 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Mar 19, 2025

    Healthy Volunteers · COMPLETED · sponsor: Bristol-Myers Squibb · A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

    ClinicalTrials.gov · NCT06877702 (opens the source filing in a new tab)

  13. Trial

    PHASE3 registered

    Mar 13, 2025

    Juvenile Psoriatic Arthritis · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

    ClinicalTrials.gov · NCT06869551 (opens the source filing in a new tab)

  14. Trial

    PHASE1/PHASE2 registered

    Feb 17, 2025

    Advanced Solid Tumors · RECRUITING · sponsor: Bristol-Myers Squibb · A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT06697197 (opens the source filing in a new tab)

  15. Trial

    PHASE1 registered

    Feb 10, 2025

    Healthy Volunteers · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

    ClinicalTrials.gov · NCT06746402 (opens the source filing in a new tab)

  16. Trial

    PHASE1 registered

    Jan 23, 2025

    Healthy Participants · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

    ClinicalTrials.gov · NCT06851871 (opens the source filing in a new tab)

  17. Trial

    PHASE1 registered

    Dec 12, 2024

    Healthy Volunteers · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

    ClinicalTrials.gov · NCT06715683 (opens the source filing in a new tab)

  18. Trial

    PHASE1 registered

    Jun 10, 2024

    Hepatic Impairment, Healthy Participants · COMPLETED · sponsor: Bristol-Myers Squibb · Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

    ClinicalTrials.gov · NCT06425198 (opens the source filing in a new tab)

  19. Trial

    PHASE2 registered

    Mar 20, 2024

    Alzheimer Disease, Early Onset · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

    ClinicalTrials.gov · NCT06268886 (opens the source filing in a new tab)

  20. Trial

    PHASE1 registered

    Mar 6, 2024

    Dermatitis, Atopic · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

    ClinicalTrials.gov · NCT06248814 (opens the source filing in a new tab)

  21. Trial

    PHASE1 registered

    Jan 29, 2024

    Healthy Participants · TERMINATED · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

    ClinicalTrials.gov · NCT06144697 (opens the source filing in a new tab)

  22. Trial

    PHASE1/PHASE2 registered

    Dec 29, 2023

    Relapsed/Refractory Non-Hodgkin Lymphoma · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

    ClinicalTrials.gov · NCT06090539 (opens the source filing in a new tab)

  23. Trial

    PHASE1/PHASE2 registered

    Nov 20, 2023

    Relapsed or Refractory T-cell Lymphomas · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

    ClinicalTrials.gov · NCT06035497 (opens the source filing in a new tab)

  24. Trial

    PHASE3 registered

    Oct 25, 2023

    Progressive Pulmonary Fibrosis · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

    ClinicalTrials.gov · NCT06025578 (opens the source filing in a new tab)

  25. Trial

    PHASE1 registered

    Sep 21, 2023

    Lupus · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

    ClinicalTrials.gov · NCT06013995 (opens the source filing in a new tab)

  26. Trial

    PHASE1 registered

    Jul 4, 2023

    Healthy Volunteers · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

    ClinicalTrials.gov · NCT05866627 (opens the source filing in a new tab)

  27. Trial

    PHASE2 registered

    Jan 18, 2023

    Cardiomyopathy, Hypertrophic · TERMINATED · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

    ClinicalTrials.gov · NCT05556343 (opens the source filing in a new tab)

  28. Trial

    PHASE1/PHASE2 registered

    Oct 18, 2022

    Multiple Myeloma · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT05372354 (opens the source filing in a new tab)

  29. Trial

    PHASE1/PHASE2 registered

    Mar 22, 2021

    Myelofibrosis · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

    ClinicalTrials.gov · NCT04817007 (opens the source filing in a new tab)

  30. Trial

    PHASE3 registered

    Aug 12, 2019

    Psoriasis · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

    ClinicalTrials.gov · NCT04036435 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources